Caroll Tipian

Learn More
PURPOSE Both heat shock protein 90 (Hsp90) and checkpoint kinase 1 (Chk1) have emerged as novel therapeutic targets. We conducted a phase I study of irinotecan and the Hsp90 inhibitor 17AAG, which can also down-regulate Chk1, in patients with solid tumors. EXPERIMENTAL DESIGN During the dose escalation phase, patients received i.v. irinotecan followed by(More)
  • 1